Stocktoria
Hikma Pharmaceuticals PLC HIK.L
GB · London Stock Exchange · XLON · stock · Healthcare · website
Hikma Pharmaceuticals PLC financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $3.3B | $3.1B | $2.9B | $2.5B |
| Gross profit | $1.4B | $1.4B | $1.4B | $1.2B |
| R&D expense | $151.0M | $141.0M | $149.0M | $144.0M |
| SG&A expense | $566.0M | $568.0M | $544.0M | $615.0M |
| Operating income | $633.0M | $612.0M | $610.0M | $482.0M |
| Interest expense | $88.0M | $75.0M | $73.0M | $59.0M |
| Income tax | $112.0M | $93.0M | $89.0M | $42.0M |
| Net income | $402.0M | $359.0M | $190.0M | $188.0M |
| EPS (diluted) | $1.81 | $1.61 | $0.85 | $0.84 |
| Operating cash flow | $436.0M | $564.0M | $608.0M | $585.0M |
| Free cash flow | $119.0M | $329.0M | $404.0M | $360.0M |
| Cash & equivalents | $217.0M | $188.0M | $205.0M | $270.0M |
| Inventory | $1.1B | $986.0M | $891.0M | $776.0M |
| Total assets | $5.7B | $5.1B | $4.7B | $4.5B |
| Total liabilities | $3.1B | $2.8B | $2.5B | $2.3B |
| Shareholders' equity | $2.6B | $2.3B | $2.2B | $2.1B |
Growth · year-over-year · Revenue CAGR 10%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +7.1% | +8.8% | +14.2% | — |
| Net income growth | +12.0% | +88.9% | +1.1% | — |
| EPS growth | +12.4% | +89.4% | +1.7% | — |
| Free cash flow growth | -63.8% | -18.6% | +12.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · GB · as of 2025-12-31. Figures in GBp; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.